EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Beta-2-Like

Ensembl ID : ENSLBEG00000016426
Gene Symbol: LOC109997070
3 Cross references
203 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233-Like

Ensembl ID : ENSLBEG00000011257
Gene Symbol: LOC110001116
3 Cross references
220 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSLBEG00000026969
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSLBEG00000027865
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSLBEG00000004881
Gene Symbol: LOC109983592
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSLBEG00000025822
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSLBEG00000020399
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSLBEG00000023251
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSLBEG00000011668
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSLBEG00000025571
Gene Symbol: SLC6A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSLBEG00000011667
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSLBEG00000021954
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).